Exit pathways of therapeutic antibodies from the brain and retention strategies

Treating brain diseases requires therapeutics to pass the blood-brain barrier (BBB) which is nearly impermeable for large biologics such as antibodies. Several methods now facilitate crossing or circumventing the BBB for antibody therapeutics. Some of these exploit receptor-mediated transcytosis, ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Schellhammer, Linda, Beffinger, Michal, Salazar, Ulisse, Laman, Jon D., Buch, Thorsten, vom Berg, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616392/
https://www.ncbi.nlm.nih.gov/pubmed/37915602
http://dx.doi.org/10.1016/j.isci.2023.108132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616392/
https://www.ncbi.nlm.nih.gov/pubmed/37915602
http://dx.doi.org/10.1016/j.isci.2023.108132

Ejemplares similares